Added to YB: 2026-05-08
Pitch date: 2026-05-07
CYTK [neutral]
Cytokinetics, Incorporated
Author Info
No bio for this author
Company Info
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States.
Market Cap
$9.6B
Pitch Price
N/A
Price Target
100.00 (+34%)
Dividend
N/A
EV/EBITDA
-16.24
P/E
-11.27
EV/Sales
96.56
Sector
Biotechnology
Category
growth
Cytokinetics | A lot of news! Everything's starting to click!
CYTK (update): ACACIA-HCM Ph3 met dual primary endpoints in nHCM: KCCQ-CSS +3pts (p=0.021), pVO2 +0.67 mL/kg/min (p=0.003). sNDA accepted, PDUFA Nov 14 2026. Q1 launch >275 HCPs, ~680 pts, $4.8M rev. Through Apr: 425 HCPs, ~1.1K pts, 70% paid scripts. >30% new-to-brand share vs Camzyos. $5B peak sales potential, simpler REMS/DDI vs competitor. $650M offering announced, ~$1.1B cash
Read full article (4 min)